Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.

Collaboration to Test New COVID-19 Drug in First Clinical Trial Worldwide

new covid-19 drug
Sheba and Merck & Co., Inc. collaborate to trial a novel coronavirus drug that prevents replication of the virus.

Sheba Medical Center is the first hospital in the world to collaborate with Merck & Co., Inc., to conduct a COVID-19 clinical trial of their drug, Molnupiravir (MK-4482). Originally designed to combat the flu, the medication is being tested as a treatment for COVID-19 patients who have symptoms and were diagnosed within the last 10 days. It is intended to be taken for five days at 12-hour intervals.

The drug works by causing mutations in the enzyme responsible for replicating the virus. By blocking replication, the disease is prevented from worsening – effectively stopping it.

Presently, Molnupiravir is in Phase II/III clinical trial to test safety and efficacy. If it is found to be safe and effective, the drug is expected to be approved at the end of the trial as a treatment for patients who are both in and out of the hospital. The COVID-19 clinical trial will continue in other international hospitals.

Thus far, Phase I results in US trials have been promising. Preclinical trials last spring also produced encouraging results, both in cells and in animals.

News Mar 26.
West Bank and Gaza Medical Professionals Attend a Milestone Sheba Oncology Conference
Highlighting the latest in cancer care, with a particular focus on pediatrics, the Recent Advances in Cancer Care (REACT) 2023 event was attended by over…
Read More
Isenia’s Battle
Isenia’s Battle with Alveolar Sarcoma
At 17, Isenia, a native of Semey, Kazakhstan, noticed a lump on her leg the size of a small apple. Initially, Isenia and her family…
Read More
Colon and Rectal Cancer
News Mar 14.
Sheba Study Indicates Readily-Available Drugs May Prevent Metastasis in Colon and Rectal Cancer Patients
Favorable responses to the treatment were noted by Prof. Shamgar Ben-Eliyahu, a neuroscientist specializing in psychoneuroimmunology (PNI) at TAU’s Sagol School of Neuroscience and School…
Read More